Versameb Announces Publication in Molecular Therapy – Nucleic Acids Journal Demonstrating the Potential of Engineered IGF-I mRNA as a Regenerative Therapeutic
Basel, Switzerland, 12 December 2023: Versameb AG (“Versameb”), a pre-clinical stage company focused on transforming RNA therapeutics to treat unmet medical needs, today announced the publication of a scientific manuscript in the internationally recognized scientific journal, Molecular Therapy – Nucleic Acids.
The paper, entitled ‘Local application of engineered insulin-like growth factor I mRNA demonstrates regenerative therapeutic potential in vivo’, highlights recent findings, which further demonstrate the therapeutic potential of engineered IGF-I mRNA as a regenerative medicine with a favorable safety profile.
